CCR 20th Anniversary Commentary: A genetic mechanism of imatinib resistance in gastrointestinal stromal tumor—Where are we a decade later? Journal Article

   

Authors:	Antonescu, C. R.; DeMatteo, R. P.
Article Title:	CCR 20th Anniversary Commentary: A genetic mechanism of imatinib resistance in gastrointestinal stromal tumor—Where are we a decade later?
Abstract:	In the June 1, 2005, issue of Clinical Cancer Research, Antonescu and colleagues defined second-site KIT mutations in gastrointestinal stromal tumor (GIST) as the leading mechanism of acquired resistance to imatinib. Secondary mutations were detectable mainly in KIT exon 11 mutant GISTs after prolonged initial clinical responses. These findings played a critical role in designing the next generation of tyrosine kinase inhibitors. ©2015 American Association for Cancer Research.
Keywords:	genetics; mutation; gastrointestinal stromal tumors; drug resistance; drug resistance, neoplasm; pyrimidines; piperazines; piperazine derivative; pyrimidine derivative; humans; human; male; female
Journal Title:	Clinical Cancer Research
Volume:	21
Issue:	15
ISSN:	1078-0432
Publisher:	American Association for Cancer Research
Date Published:	2015-08-01
Start Page:	3363
End Page:	3365
Language:	English
DOI:	10.1158/1078-0432.ccr-14-3120
PUBMED:	26240289
PROVIDER:	scopus
PMCID:	PMC4526110
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964696746&partnerID=40&md5=779e0d19685ba33024526aada4ec423f
Notes:	Note -- Export Date: 2 June 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/93779